Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery

NCT00721760 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1003

Enrollment

INDUSTRY

Sponsor class

Conditions

Venous Thromboembolism

Interventions

DRUG: Enoxaparin sodium
DRUG: Semuloparin sodium
DRUG: Placebo

Sponsor

Sanofi